Holen Sie sich die Stockscreener-App
1.54
2.67%
0.04
Handel nachbörslich:
1.52
-0.02
-1.30%
Schlusskurs vom Vortag:
$1.50
Offen:
$1.53
24-Stunden-Volumen:
1.24M
Relative Volume:
1.12
Marktkapitalisierung:
$316.01M
Einnahmen:
$889.00K
Nettoeinkommen (Verlust:
$-156.28M
KGV:
-2.9239
EPS:
-0.5267
Netto-Cashflow:
$-150.06M
1W Leistung:
-1.28%
1M Leistung:
-15.85%
6M Leistung:
-30.32%
1J Leistung:
-53.19%
1-Tages-Spanne:
$1.52
$1.61
1-Wochen-Bereich:
$1.45
$1.61
52-Wochen-Spanne:
$1.45
$3.55
Prokidney Corp Stock (PROK) Company Profile
Firmenname
Prokidney Corp
Sektor
Branche
Telefon
336-999-7028
Adresse
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.54 | 307.80M | 889.00K | -156.28M | -150.06M | -0.5267 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-06-30 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-30 | Eingeleitet | JP Morgan | Neutral |
| 2024-09-10 | Eingeleitet | Guggenheim | Buy |
| 2024-03-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-07-25 | Eingeleitet | BTIG Research | Buy |
| 2022-12-21 | Eingeleitet | Jefferies | Buy |
| 2022-11-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-10-18 | Eingeleitet | UBS | Buy |
| 2022-10-14 | Eingeleitet | Citigroup | Buy |
| 2022-09-23 | Eingeleitet | BofA Securities | Buy |
| 2022-09-02 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Prokidney Corp Aktie (PROK) Neueste Nachrichten
ProKidney Corp (PROK) Income Statement - TradingKey
ProKidney Corp (PROK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PROK|ProKidney Corp|Price:1.500|Chg%:-0.020 - TradingKey
ProKidney Corp (PROK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ProKidney Corp (PROK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ProKidney Corp (PROK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
ProKidney Corp (PROK) Cash Flow - TradingKey
PROK|ProKidney Corp|Price:1.504|Chg%:+0.004 - TradingKey
ProKidney Corp (PROK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ProKidney (NASDAQ:PROK) Trading Down 0.7%Time to Sell? - MarketBeat
ProKidney Corp. (PROK) Q1 2026 Earnings: In-Line EPS, Pre-Revenue Progress Drives Modest Stock GainROA Comparison - dars.gov.et
Meet the Biotech Stock That Rocketed 775% Higher - MSN
ProKidney Corp (PROK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ProKidney Corp. Q1 2026 Earnings: Clinical-Stage Biotech Posts Narrower-Than-Expected Loss, Shares RallyEPS Revision Trend - dars.gov.et
ProKidney Corp. (PROK) Declines Sharply: Key Support Level Under ScrutinyMFI Overbought - dars.gov.et
ProKidney Corp. (PROK) Q1 2026 Earnings: Narrowed Loss Slightly Beats Estimates Amid Pipeline Focus - dars.gov.et
ProKidney (NASDAQ:PROK): Can This Penny Stock Rebound? - Kalkine Media
What Makes ProKidney Corp (NASDAQ:PROK) Stand Out on Nasdaq Composite? - Kalkine Media
ProKidney Corp. (PROK) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEstimate Uncertainty - dars.gov.et
ProKidney (PROK) 43rd Annual J.P. Morgan Healthcare Conference 2025 Summary - Quartr
ProKidney (NASDAQ: PROK) CTO awarded 750,000 stock options at $1.89 strike - Stock Titan
July 2026 Penny Stocks With Promising Potential - simplywall.st
PROK Q1 2026 Earnings: EPS Slightly Exceeds Estimates as Clinical Progress ContinuesRevenue Guidance Range - dars.gov.et
PROKProKidney Corp Short Interest - Finviz
Is ProKidney (NASDAQ:PROK) In A Good Position To Invest In Growth? - 富途牛牛
ProKidney Corp. (PROK) Rallies 7.4%: Biotech Stock Approaches Key Resistance LevelFactor Crowding - dars.gov.et
ProKidney Corp. (PROK) Q1 2026 Earnings: Narrower Loss, No Revenue, Shares Gain Post-ReportEarnings Call Highlights - dars.gov.et
ProKidney Corp.(NasdaqCM: PROK) added to Russell 2000 Index - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell Microcap Value Benchmark Index - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell 2000 Value Benchmark - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell Microcap Growth Benchmark Index - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell 2000 Growth Benchmark - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell 3000E Growth Benchmark - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell Microcap Index - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell 2500 Value Benchmark - marketscreener.com
Price to earnings forward of ProKidney Corp. – NASDAQ:PROK - TradingView
Price to earnings forward of ProKidney Corp. Class A – BMV:PROK - TradingView
Price to sales forward of ProKidney Corp. – NASDAQ:PROK - TradingView
Enterprise value to revenue forward of ProKidney Corp. – NASDAQ:PROK - TradingView
Enterprise value to EBIT forward of ProKidney Corp. Class A – BMV:PROK - TradingView
Enterprise value to EBITDA forward of ProKidney Corp. – NASDAQ:PROK - TradingView
Price to sales forward of ProKidney Corp. Class A – BMV:PROK - TradingView
ProKidney Corp (PROK) Valuation: PE, PB & Fair Value Analysis - TradingKey
ProKidney Corp. Class A Actuals & Estimates (NASDAQ:PROK) - TradingView
ProKidney Corp. (PROK) Faces Selling Pressure Near Resistance – Key Levels in FocusDouble EMA - dars.gov.et
PROK Forecast — Price Target — Prediction for 2027 - TradingView
ProKidney (PROK) Study Update Summary - Quartr
ProKidney Corp (PROK) Institutional Confidence - TradingKey
ProKidney Corp. (PROK) Slips 1.67% as Stock Tests Key Support at $1.68Fast Moving Stocks - dars.gov.et
PROK Q1 2026 Earnings: Narrower Loss Than Expected Lifts SharesEPS Miss Report - dars.gov.et
Finanzdaten der Prokidney Corp-Aktie (PROK)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):